$4.75 -0.2 -4.4%
Last Trade - 15/01/21
| Market Cap | £331.4m |
| Enterprise Value | £397.0m |
| Revenue | £276.7m |
| Position in Universe | 3381st / 6543 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 379.8 | 398.8 | 383.4 | 404.9 | 418.8 | 382.9 | 381.7 | 419.5 | +0.2% | ||
| +272.7 | ||||||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.
| Last Annual | June 30th, 2020 |
| Last Interim | September 30th, 2020 |
| Incorporated | February 22, 2001 |
| Public Since | February 8, 2007 |
| No. of Shareholders: | 193 |
| No. of Employees: | 932 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Global Select Market |
| Shares in Issue | 91,273,683 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1310 Chesapeake Ter, SUNNYVALE, 94089-1100, United States |
| Web | http://www.accuray.com/ |
| Phone | +1 408 7164600 |
| Contact | Joe Diaz (Investor Relations) |
| Auditors | Grant Thornton LLP |
As of 15/01/21, shares in Accuray Inc are trading at $4.75, giving the company a market capitalisation of £331.4m. This share price information is delayed by 15 minutes.
Shares in Accuray Inc are currently trading at $4.75 and the price has moved by 52.92% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Accuray Inc price has moved by 33.13% over the past year.
Of the analysts with advisory recommendations for Accuray Inc, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Accuray Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Accuray Inc is scheduled to issue upcoming financial results on the following dates:
Accuray Inc does not currently pay a dividend.
Accuray Inc does not currently pay a dividend.
Accuray Inc does not currently pay a dividend.
To buy shares in Accuray Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Accuray Inc are currently trading at $4.75, giving the company a market capitalisation of £331.4m.
Here are the trading details for Accuray Inc:
Based on an overall assessment of its quality, value and momentum, Accuray Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Accuray Inc are currently priced at $4.75. At that level they are trading at 40.85% discount to the analyst consensus target price of 0.00.
Analysts covering Accuray Inc currently have a consensus Earnings Per Share (EPS) forecast of 0.022 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Accuray Inc. Over the past six months, the relative strength of its shares against the market has been 93.7%. At the current price of $4.75, shares in Accuray Inc are trading at 78.06% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Accuray Inc PE ratio based on its reported earnings over the past 12 months is 33.08. The shares are currently trading at $4.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Accuray Inc's management team is headed by:
Here are the top five shareholders of Accuray Inc based on the size of their shareholding:
